Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients
- PMID: 28940943
- PMCID: PMC5668489
- DOI: 10.1111/1759-7714.12489
Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients
Abstract
Background: This retrospective study was conducted to investigate the relationship between epidermal growth factor receptor (EGFR) mutation and histological subtypes of lung adenocarcinoma according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification in Chinese patients.
Methods: Three hundred and seventy six surgically resected lung adenocarcinomas from Chinese PLA General Hospital were included in the study. Patients' clinical and pathological characteristics including age, gender, smoking history, tumor size, tumor node metastasis stage, and tumor differentiation were analyzed. Histologic subtypes of adenocarcinoma were categorized according to the IASLC/ATS/ERS classification of lung adenocarcinoma. An amplification-refractory mutation system was performed to detect EGFR mutations.
Results: One hundred and fifty three lung adenocarcinomas had EGFR mutations. In univariate analysis, EGFR mutations were associated with gender (P < 0.001), smoking history (P < 0.001), tumor differentiation (P < 0.001), and acinar predominant (P < 0.001), papillary predominant (P = 0.034), solid predominant (P = 0.022), invasive mucinous (P = 0.012) and mucinous (P = 0.001) subtypes.
Conclusions: In Chinese patients with lung adenocarcinoma, smoking history, tumor differentiation, and acinar predominant and mucinous subtypes were independent predictors of EGFR mutation.
Keywords: EGFR mutation; lung adenocarcinoma; pathology.
© 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
References
-
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. (Published erratum appears in CA Cancer J Clin 2011; 61: 134.) CA Cancer J Clin 2011; 61: 69–90. - PubMed
-
- Shin HR, Masuyer E, Ferlay J, Curado MP. Asian contributors to CI5 IX4. Cancer in Asia – Incidence rates based on data in cancer incidence in five continents IX (1998–2002). Asian Pac J Cancer Prev 2010; 11 (Suppl. 2): 11–6. - PubMed
-
- Pao W, Miller VA. Epidermal growth factor receptor mutations, small‐molecule kinase inhibitors, and non‐small‐cell lung cancer: Current knowledge and future directions. J Clin Oncol 2005; 23: 2556–68. - PubMed
-
- Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G. The correlation of the international association for the study of lung cancer (IASLC)/american thoracic society (ATS)/european respiratory society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 2014; 98: 453–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
